The US Food and Drug Administration approved a novel oral medication for the treatment of metastatic pancreatic cancer on the 26th, providing new treatment options for some patients with advanced pancreatic cancer. According to the US Drug Administration, this oral drug called Rasonque was developed by the US “Revolutionary” pharmaceutical company. It is an oral tablet to be taken once a day and targets RAS protein. RAS is an important driver of multiple tumor growth and plays a key role in tumor growth in most patients with pancreatic cancer. The drug has now been approved for adult patients with metastatic pancreatic adenocarcinoma who have received at least one systemic treatment, or who are unfit to receive multi-drug combined systemic treatment. According to the US National Cancer Institute, about 90% to 95% of the approximately 67,000 new pancreatic cancer cases diagnosed in the US each year are pancreatic cancer. Although pancreatic cancer accounts for only 3.2% of all cancer diagnoses, it accounts for a significantly higher proportion of deaths due to usually late detection, rapid progression, and limited treatment options over a long period of time. The US Drug Administration said that a randomized, open-label, multi-center clinical trial included 500 previously treated adult patients with metastatic pancreatic cancer. Results showed that the median overall survival time for patients treated with Rasonque was 13.2 months compared to patients receiving standardized treatment, while patients receiving standardized treatment were 6.7 months. According to reports, the most common adverse effects of the drug include rashes, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, loss of appetite, and bleeding. The US Drug Administration has previously granted Rasonque “breakthrough therapy” and “orphan drug” certification, and has given priority review to its relevant indications.

The US Food and Drug Administration approved a novel oral medication for the treatment of metastatic pancreatic cancer on the 26th, providing new treatment options for some patients with advanced pancreatic cancer. According to the US Drug Administration, this oral drug called Rasonque was developed by the US “Revolutionary” pharmaceutical company. It is an oral tablet to be taken once a day and targets RAS protein. RAS is an important driver of multiple tumor growth and plays a key role in tumor growth in most patients with pancreatic cancer. The drug has now been approved for adult patients with metastatic pancreatic adenocarcinoma who have received at least one systemic treatment, or who are unfit to receive multi-drug combined systemic treatment. According to the US National Cancer Institute, about 90% to 95% of the approximately 67,000 new pancreatic cancer cases diagnosed in the US each year are pancreatic cancer. Although pancreatic cancer accounts for only 3.2% of all cancer diagnoses, it accounts for a significantly higher proportion of deaths due to usually late detection, rapid progression, and limited treatment options over a long period of time. The US Drug Administration said that a randomized, open-label, multi-center clinical trial included 500 previously treated adult patients with metastatic pancreatic cancer. Results showed that the median overall survival time for patients treated with Rasonque was 13.2 months compared to patients receiving standardized treatment, while patients receiving standardized treatment were 6.7 months. According to reports, the most common adverse effects of the drug include rashes, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, loss of appetite, and bleeding. The US Drug Administration has previously granted Rasonque “breakthrough therapy” and “orphan drug” certification, and has given priority review to its relevant indications.